Saniona AB (STO:SANION), a clinical stage biotechnology company focused on rare diseases of the Central Nervous System, announced on Tuesday that Thomas Feldthus, co-founder and CFO, will be leaving the company.
According to Saniona, as a part of its strategic transformation it has initiated the search for a new CFO, who will be based in the US along with CEO Rami Levin. Feldthus, who is one of the co-founders of Saniona, will continue as CFO for an interim period to ensure a smooth transition and transfer of responsibilities to the new CFO.
Rami Levin, CEO of Saniona, stated that the company is rapidly advancing Tesomet towards pivotal clinical trials in the rare eating disorders Prader-Willi Syndrome and Hypothalamic Obesity. The expansion of its US organisation is a vital step towards its longer-term aim of becoming a global, commercial-stage company.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference